-
Product Insights
NewNet Present Value Model: Otsuka Holdings Co Ltd’s Sibeprenlimab
Empower your strategies with our Net Present Value Model: Otsuka Holdings Co Ltd's Sibeprenlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Immunocore Holdings Plc’s IMCF-106C
Empower your strategies with our Net Present Value Model: Immunocore Holdings Plc's IMCF-106C report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Morphic Holding Inc’s MORF-057
Empower your strategies with our Net Present Value Model: Morphic Holding Inc's MORF-057 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Cerevel Therapeutics Holdings Inc’s Tavapadon
Empower your strategies with our Net Present Value Model: Cerevel Therapeutics Holdings Inc's Tavapadon report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Oculis Holding AG’s Dexamethasone Acetate
Empower your strategies with our Net Present Value Model: Oculis Holding AG's Dexamethasone Acetate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Corbus Pharmaceuticals Holdings Inc’s SYS-6002
Empower your strategies with our Net Present Value Model: Corbus Pharmaceuticals Holdings Inc's SYS-6002 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Freeline Therapeutics Holdings Plc’s FLT-201
Empower your strategies with our Net Present Value Model: Freeline Therapeutics Holdings Plc's FLT-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arcturus Therapeutics Holdings Inc’s ARCT-810
Empower your strategies with our Net Present Value Model: Arcturus Therapeutics Holdings Inc's ARCT-810 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
NewHilton Worldwide Holdings Inc – Digital Transformation Strategies
Hilton Worldwide Holdings Digital Transformation Strategies Overview Hilton has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Hilton was estimated at $639.4 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Hilton Worldwide Holdings Inc (HWHI) is a global hospitality company. It operates a chain of luxury and full-service hotels and resorts, extended-stay...
-
Product Insights
NewBactiguard Holding AB Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Bactiguard Holding AB Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Bactiguard Holding AB (Bactiguard) is a medical device manufacturer that develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. It also provides services in the field of infection protection mechanism to treat urinary tract, the respiratory tract and the bloodstream problems. Its...